This is an ongoing phase II trial recruiting HER2+ BC patients with anatomic stage II–III to compare the combination paclitaxel and pertuzumab with either margetuximab or trastuzumab in the neoadjuvant setting [140]. The gene discussed is ERBB2; the disease is breast cancer.